Immatics N.v. · NASDAQ:IMTX
Immatics — European Society of Medical Oncology Congress 2024
30 slides from Immatics's conference presentation, Sep 16, 2024
Slide 1: TCR Bispecific Molecule TCER IMA401 Targeting MAGEA4/8 - Phase 1 Dose Escalation Clinical Data Update
TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 - Phase 1 Dose Escalation Clinical Data Update September 16, 2024 Oral presentation by Martin Wermke at the European Society of Medical Oncology Congress 2024 on September 16, 2024 Data cut - off Jul 23, 2024 Delivering the Power of T cells to
Slide 2: Forward-Looking Statement
Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their resp
Slide 3: IMA401: Next-Generation Bispecific TCER Targeting MAGEA4/8
IMA401: Next - Generation Bispecific TCER® Targeting MAGEA4/8 Designed to Efficiently Target Tumor - specific Peptides (pHLA) 1 Data presented at ESMO 2022 3 High - affinity TCR domains targeting proprietary high copy - number MAGEA4/8 - derived HLA - A*02 - presented peptide L o w - a ffi n ity T c
Slide 4: Potency of Our Proprietary TCR Bispecific Format TCER
Potency of Our Proprietary TCR Bispecific Format TCER® 4 • Seven different TCR Bispecific formats were evaluated with a pHLA targeting TCR and the identical T cell recruiting antibody • TCER® format had higher combination of potency and specificity 2 than six alternative TCR Bispecific format design
Slide 5: TCER IMA401 Targeting MAGEA4/8: Higher Target Density of MAGEA4/8 Peptide
TCER® IMA401 Targeting MAGEA4/8 Higher Target Density of MAGEA4/8 Peptide 5 MAGEA4 protein detection in tumor samples (IHC) 1 MAGEA4/8 target prevalences are based on TCGA and in - house data combined with a XPRESIDENT® - determined target individual MS - based mRNA expression threshold; qPCR - thre
Slide 6: Trial Design – IMA401-101 Phase 1a Dose Escalation
6 180 µg 540 µg 1800 µg 2500 µg Key Eligibility Criteria Object iv es Primary: • Determine MTD and/or RP2D Secondary: • Tolerability • Pharmacokinetics • Initial anti - tumor activity • Recurrent and/or refractory solid tumors • HLA - A*02:01 positive • MAGEA4/8 - positive as confirmed by mRNA - ba
Slide 7: Baseline Characteristics: Heavily Pre-treated Patients with a Broad Range of Tumor Types
Baseline Characteristics Heavily Pre - treated Patients with a Broad Range of Tumor Types 7 1 Efficacy Analysis Set (EAS) prospectively defined in the study protocol: patients who received at least four IMA401 infusions and had at least one post - baseline efficacy assessment or clinical progression
Slide 8: IMA401 Demonstrates Manageable Tolerability in N=35 Patients
8 IMA401 Demonstrates Manageable Tolerability in N=35 Patients Most Frequent Related AEs were Lymphopenia, CRS and Neutropenia ≥ Grade 3 All Grades TEAEs, n [%] 26 [74] 32 [91] Any 19 [54] 28 [80] Treatment - related ≥ Grade 3 All Grades Treatment - related AEs 1 , n [%] 11 [31] 12 [34] Lymphopenia
Slide 9: IMA401 Pharmacokinetics: TCER Format Shows Extended Half-Life in Solid Cancer Patients
IMA401 Pharmacokinetics TCER® Format Shows Extended Half - Life in Solid Cancer Patients 1 Half - lifes derived from 2nd PK profiles close to steady - state. Calculated by non - compartmental analysis (NCA) using Phoenix WinNonlin (Certara); Interquartile range (25% - 75% percentile): 13.5 - 22.2 da
Slide 10: IMA401 Demonstrates Initial Anti-Tumor Activity in Multiple Tumor Types
IMA401 Demonstrates Initial Anti - Tumor Activity in Multiple Tumor Types Phase 1a Dose Escalation Across All Dose and Target Levels (DL1 - 7; N=29 * ) 10 * Patients of the Efficacy Analysis Set with at least one post - treatment tumor assessment shown; two patients are not shown as they had clinica
Slide 11: Objective Responses are Associated with Target Expression
1 Patients in this analysis had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression above indicated MAGEA4/A8 high qPCR threshold (n=17); PD: Progressive disease; PR: Partial response; cPR: confirmed Partial response; SD: Stable disease. 11 Data cut - off Jul 23, 2024 Objective
Slide 12: IMA401 Demonstrates Initial Anti-Tumor Activity
12 *Patients in this analysis are part of the efficacy analysis set with at least one post - treatment tumor assessment and had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression higher than the MAGEA4/8 qPCR threshold (n=17); Confirmed ORR (cORR): Confirmed objective response
Slide 13: Tumor Shrinkage and Disease Control Associated with Prolonged Overall Survival
Tumor Shrinkage and Disease Control Induced by IMA401 Associated with Prolonged Overall Survival Analysis Across All Doses and Target Levels (DL1 - 7) 13 12.7 months median OS across multiple tumor types and all dose levels (n=29) Tumor shrinkage (12/27 patients) and disease control (16/29) associat
Slide 14: Clinical Activity in Heavily Pre-Treated Cancer Patients
Clinical Activity in Heavily Pre - Treated Cancer Patients 14 CT and MRI scans courtesy of treating physicians (Dr. Manik Chatterjee, University Hospital Wuerzburg and Dr. Max - Felix Häring, Eberhard Karls University Tue bingen); HNSCC: Head and neck squamous cell carcinoma; NET CUP: Neuroendocrine
Slide 15: First-in-human Data of IMA401 TCER Targeting MAGEA4/8
First - in - human Data of IMA401 TCER® Targeting MAGEA4/8 • Tolerability : Most common treatment - related AEs are low - grade CRS, transient lymphopenia and neutropenia • Pharmacokinetics : Median terminal half - life of 16.9 days supporting potential further flexibility in future dosing schedules
Slide 16: Special Thanks to the Patients, their Families and Investigators
Special Thanks to the Patients, their Families 16 B o n n Dresden Tuebingen Heidelberg Ulm Wuerzburg Erlangen Mun i c h Reg en s bu rg Duesseldorf M a i n z Chemnitz B e rlin Leipz i g Freib u rg Nuremberg Muenster K i e l Sponsor: Immatics …and the IMA401 Investigators at the Clinical Sites Dresden
Slide 17: Appendix
A p pen d ix Confidential 17
Slide 18: IMA401 Demonstrates Initial Anti-Tumor Activity in Multiple Tumor Types
IMA401 Demonstrates Initial Anti - Tumor Activity in Multiple Tumor Types Phase 1a Dose Escalation Across All Dose and Target Levels (DL1 - 7; N=29 * ) 18 # of Patients Safety (Efficacy - evaluable) Population 16 Different Indications 7 (7) Cut. Melanoma 1 (1) Muc. Melanoma 6 (3) Synovial Sarcoma 4
Slide 19: IMA401 Initial Anti-Tumor Activity: Patients at Relevant Doses
19 * Patients of the Efficacy Analysis Set with at least one post - treatment tumor assessment shown; Two patients are not shown as they had clinical progression and post - treatment tumor assessment is not available. BOR for one cut. melanoma patient is presented as SD as per iRECIST while BOR per
Slide 20: Objective Responses are Associated with Target Expression
1 Patients in this analysis had received IMA 401 infusions at ≥ 1 mg and showed MAGEA 4 / 8 target expression higher than the MAGEA 4 / 8 qPCR threshold (N= 17 ) ; DCR : Disease Control Rate ; ORR : Objective Response Rate ; Confirmed objective response rate (cORR) according to RECIST 1 . 1 for pati
Slide 21: Level of PD-L1 Expression is Associated with Clinical Outcome
21 Level of PD - L1 Expression is Associated with Clinical Outcome Responses as per RECIST 1.1 (PR/cPR) are seen mainly in tumors with low PD - L1 expression • • In line with proposed resistance mechanism of tumor cells sqNSCLC and HNSCC known to express high PDL1 levels and have approved CPI therap
Slide 22: MAGEA4/8 Target Expression Profiles Across Selected Tumor Types
MAGEA4/8 Target Expression Profiles Across Selected Tumor Types 22 Data cut - off Jul 23, 2024 qPCR - threshold MAGEA4/8 high qPCR - threshold for patient screening 31% 36% 41% 52% 15% 18% Target Prevalences 1 MAGEA4/8 target expression distribution (blue histogram) based on TCGA RNAseq data; 1 MAGE
Slide 23: Initial Anti-Tumor Activity – Subanalysis of Melanoma Patients
23 Initial Anti - Tumor Activity – Subanalysis of Melanoma Patients Phase 1a Dose Escalation Across All Dose and Target Levels (DL1 - DL7; N=8*) 0 1 2 3 4 10 11 12 13 14 - 1 0 0 - 5 0 0 50 1 0 0 5 6 7 8 9 Months post First IMA401 Infusion Change in Sum of Longest Diameter of Target Lesions from Base
Slide 24: Baseline Characteristics – Subanalysis of Melanoma Patients
Baseline Characteristics – Subanalysis of Melanoma Patients Heavily Pre - treated Melanoma Patients 24 Data cut: 23 - Jul - 2024 Safety Population: All Melanoma Patients (N=8) Characteristic Cut. Melanoma 7/8 [87.5] Muc. Melanoma 1/8 [12.5] Indications n [%] 76.5 (62, 82) Age Median (min, max) 1 [12
Slide 25: Clinical Activity in Heavily Pre-Treated Melanoma Patients
Clinical Activity in Heavily Pre - Treated Melanoma Patients 25 CT scans courtesy of treating physicians (Dr. S. Ochsenreither, Charité Berlin and Dr. M. Wermke, TU Dresden); SD: Stable disease, cPR: confirmed Partial response. Outcomes Patient Characteristics cPR - 42.6% reduction Cutaneous Melanom
Slide 26: IMA401: Initial Anti-Tumor Activity in Heavily Pretreated Patients
IMA401: Initial Anti - Tumor Activity in Heavily Pretreated Patients Phase 1a Dose Escalation Across All Dose and Target Levels, Efficacy - evaluable Population (N=29*) 26 Data cut - off Jul 23, 2024 BOR (Max % change of target lesions) B OR Baseline Tumor Burden [mm] Highest DL received List of pri
Slide 27: IMA401: Initial Anti-Tumor Activity in Heavily Pretreated Patients (cont.)
IMA401: Initial Anti - Tumor Activity in Heavily Pretreated Patients Phase 1a Dose Escalation Across All Dose and Target Levels, Efficacy - evaluable Population (N=29*) cont. 27 Data cut - off Jul 23, 2024 BOR (Max % change of target lesions) BOR Baseline Tumor Burden [mm] Highest DL received List o
Slide 28: IMA401: Initial Anti-Tumor Activity in Heavily Pretreated Patients (cont.)
IMA401: Initial Anti - Tumor Activity in Heavily Pretreated Patients Phase 1a Dose Escalation Across All Dose and Target Levels, Efficacy - evaluable Population (N=29*) cont. 28 Data cut - off Jul 23, 2024 BOR (Max % change of target lesions) BOR Baseline Tumor Burden [mm] Highest DL received List o
Slide 29: IMA401: Initial Anti-Tumor Activity in Heavily Pretreated Patients (cont.)
IMA401: Initial Anti - Tumor Activity in Heavily Pretreated Patients Phase 1a Dose Escalation Across All Dose and Target Levels, Efficacy - evaluable Population (N=29*) cont. 29 Data cut - off Jul 23, 2024 BOR (Max % change of target lesions) BOR Baseline Tumor Burden [mm] Highest DL received List o
Slide 30: www.immatics.com – Partnering and Licensing Contact
www.immatics.com Please contact us via partnering@immatics.com to learn more about partnering and licensing opportunities utilizing our platform technologies XPRESIDENT®, XCEPTOR®, IMADetect®, AbsQuant® and TCR Scout®. Thank you
Immatics — European Society of Medical Oncology Congress 2024 on 6ix